Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial
This analysis reveals gene expression subtypes predict response to neoadjuvant immune-chemotherapy in triple-negative breast cancer, suggesting implications for treatment strategies.
Key Points
To evaluate gene expression subtyping of early triple-negative breast cancer (TNBC) for predicting responses to neoadjuvant immune-chemotherapy.
Analyzed 494 pre-therapeutic biopsies for 2549 genes using the HTG EdgeSeq system.
Employed classical AIMS and TNBC subtyping methods.
Endpoints included pathological complete response (pCR) and event-free survival (EFS).
Assessed predefined gene expression signatures focusing on immune, proliferation, and stromal genes.
Classical AIMS subtyping identified 70.5% Basal-like and 23.8% HER2-enriched subtypes.
TNBC subcategories included immunomodulatory (25.5%) and Mesenchymal (23.9%).
pCR rates varied by subtype, with IM subtype achieving 74.6% pCR.
Significant immune gene expression correlated with pCR and EFS in treated patients.